Status:
UNKNOWN
Serial Epstein-Barr Virus DNA Surveillance in Nasopharyngeal Carcinoma Patients
Lead Sponsor:
Sun Yat-sen University
Conditions:
Nasopharyngeal Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
Endemic nasopharyngeal carcinoma (NPC) is invariably associated with Epstein-barr virus (EBV) infection. Plasma EBV DAN detected by polymerase chain reaction (PCR)-based assays can provide important i...
Eligibility Criteria
Inclusion
- Patients with newly histologically confirmed non-keratinizing carcinoma (according to WHO histological type)
- No evidence of distant metastasis (M0)
- Receive standard radical treatment
- Not exhibiting overt psychopathology, and willing to participate and written informed consent was obtained
Exclusion
- WHO type keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma.
- Treatment with palliative intent
- Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume)
- Severe intercurrent disease
Key Trial Info
Start Date :
May 9 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2024
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT03855020
Start Date
May 9 2019
End Date
May 1 2024
Last Update
June 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060